Windtree Therapeutics, Inc. (WINTW)
USD 0.0
(-61.11%)
USD 0.0
(-61.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 17.45 Million USD | -20.25% |
| 2022 | 21.88 Million USD | -32.15% |
| 2021 | 32.26 Million USD | 6.41% |
| 2020 | 30.31 Million USD | 20.83% |
| 2019 | 25.09 Million USD | 39.53% |
| 2018 | 17.98 Million USD | -25.17% |
| 2017 | 24.03 Million USD | -40.03% |
| 2016 | 40.07 Million USD | 0.47% |
| 2015 | 39.89 Million USD | -8.13% |
| 2014 | 43.42 Million USD | -2.16% |
| 2013 | 44.37 Million USD | 16.74% |
| 2012 | 38.01 Million USD | 51.49% |
| 2011 | 25.09 Million USD | -1.7% |
| 2010 | 25.52 Million USD | -12.57% |
| 2009 | 29.19 Million USD | -32.09% |
| 2008 | 42.99 Million USD | 7.63% |
| 2007 | 39.94 Million USD | -5.12% |
| 2006 | 42.1 Million USD | -1.27% |
| 2005 | 42.64 Million USD | 9.02% |
| 2004 | 39.11 Million USD | 53.56% |
| 2003 | 25.47 Million USD | 28.61% |
| 2002 | 19.8 Million USD | 51.48% |
| 2001 | 13.07 Million USD | 2.44% |
| 2000 | 12.76 Million USD | 137.34% |
| 1999 | 5.37 Million USD | -32.79% |
| 1998 | 8 Million USD | -19.19% |
| 1997 | 9.9 Million USD | 607.14% |
| 1996 | 1.4 Million USD | -51.72% |
| 1995 | 2.9 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 11.42 Million USD | 160.68% |
| 2024 Q1 | 4.38 Million USD | -11.6% |
| 2023 Q2 | 4.18 Million USD | 12.84% |
| 2023 Q4 | 4.95 Million USD | 5.74% |
| 2023 FY | 17.45 Million USD | -20.25% |
| 2023 Q3 | 4.69 Million USD | 12.12% |
| 2023 Q1 | 3.7 Million USD | 7.2% |
| 2022 FY | 21.88 Million USD | -32.15% |
| 2022 Q1 | 8.33 Million USD | 11.97% |
| 2022 Q2 | 5.9 Million USD | -29.17% |
| 2022 Q3 | 4.19 Million USD | -28.91% |
| 2022 Q4 | 3.45 Million USD | -17.59% |
| 2021 Q3 | 8.14 Million USD | 7.31% |
| 2021 Q2 | 7.59 Million USD | -16.38% |
| 2021 Q1 | 9.07 Million USD | 30.43% |
| 2021 FY | 32.26 Million USD | 6.41% |
| 2021 Q4 | 7.44 Million USD | -8.65% |
| 2020 Q4 | 6.96 Million USD | -20.03% |
| 2020 Q1 | 6.7 Million USD | 47.19% |
| 2020 Q2 | 7.94 Million USD | 18.57% |
| 2020 FY | 30.31 Million USD | 20.83% |
| 2020 Q3 | 8.7 Million USD | 9.52% |
| 2019 FY | 25.09 Million USD | 39.53% |
| 2019 Q4 | 4.55 Million USD | -36.64% |
| 2019 Q3 | 7.18 Million USD | 8.03% |
| 2019 Q2 | 6.65 Million USD | -0.66% |
| 2019 Q1 | 6.69 Million USD | 29.91% |
| 2018 Q3 | 3.69 Million USD | -9.54% |
| 2018 FY | 17.98 Million USD | -25.17% |
| 2018 Q1 | 5.04 Million USD | 40.11% |
| 2018 Q2 | 4.08 Million USD | -18.97% |
| 2018 Q4 | 5.15 Million USD | 39.44% |
| 2017 Q1 | 8.33 Million USD | 14.68% |
| 2017 Q2 | 7.28 Million USD | -12.57% |
| 2017 Q4 | 3.6 Million USD | -25.17% |
| 2017 Q3 | 4.81 Million USD | -33.98% |
| 2017 FY | 24.03 Million USD | -40.03% |
| 2016 FY | 40.07 Million USD | 0.47% |
| 2016 Q4 | 7.26 Million USD | -16.4% |
| 2016 Q1 | 14.01 Million USD | 34.31% |
| 2016 Q3 | 8.69 Million USD | -13.91% |
| 2016 Q2 | 10.09 Million USD | -27.95% |
| 2015 Q1 | 10.43 Million USD | -9.32% |
| 2015 Q3 | 8.5 Million USD | -19.05% |
| 2015 Q2 | 10.51 Million USD | 0.74% |
| 2015 Q4 | 10.43 Million USD | 22.65% |
| 2015 FY | 39.89 Million USD | -8.13% |
| 2014 Q4 | 11.5 Million USD | 8.6% |
| 2014 Q1 | 10.01 Million USD | 1.94% |
| 2014 Q3 | 10.59 Million USD | -6.25% |
| 2014 Q2 | 11.3 Million USD | 12.89% |
| 2014 FY | 43.42 Million USD | -2.16% |
| 2013 Q2 | 10.99 Million USD | -13.39% |
| 2013 Q4 | 9.82 Million USD | -9.67% |
| 2013 Q3 | 10.87 Million USD | -1.08% |
| 2013 Q1 | 12.69 Million USD | 0.57% |
| 2013 FY | 44.37 Million USD | 16.74% |
| 2012 Q3 | 9.99 Million USD | 13.41% |
| 2012 Q4 | 12.62 Million USD | 26.23% |
| 2012 Q2 | 8.81 Million USD | 33.98% |
| 2012 FY | 38.01 Million USD | 51.49% |
| 2012 Q1 | 6.58 Million USD | 11.47% |
| 2011 Q2 | 6.58 Million USD | 2.19% |
| 2011 Q4 | 5.9 Million USD | -4.33% |
| 2011 FY | 25.09 Million USD | -1.7% |
| 2011 Q3 | 6.17 Million USD | -6.25% |
| 2011 Q1 | 6.44 Million USD | 6.76% |
| 2010 FY | 25.52 Million USD | -12.57% |
| 2010 Q1 | 7.06 Million USD | 19.68% |
| 2010 Q2 | 6.22 Million USD | -11.85% |
| 2010 Q4 | 6.03 Million USD | -2.76% |
| 2010 Q3 | 6.2 Million USD | -0.4% |
| 2009 Q1 | 8.7 Million USD | 4.96% |
| 2009 Q3 | 6.94 Million USD | -9.12% |
| 2009 FY | 29.19 Million USD | -32.09% |
| 2009 Q2 | 7.64 Million USD | -12.17% |
| 2009 Q4 | 5.9 Million USD | -15.03% |
| 2008 FY | 42.99 Million USD | 7.63% |
| 2008 Q3 | 10.45 Million USD | -16.5% |
| 2008 Q4 | 8.29 Million USD | -20.65% |
| 2008 Q2 | 12.51 Million USD | 6.63% |
| 2008 Q1 | 11.73 Million USD | -3.65% |
| 2007 Q3 | 9.33 Million USD | -9.05% |
| 2007 Q2 | 10.25 Million USD | 25.48% |
| 2007 Q1 | 8.17 Million USD | 2.91% |
| 2007 FY | 39.94 Million USD | -5.12% |
| 2007 Q4 | 12.18 Million USD | 30.54% |
| 2006 Q3 | 7.92 Million USD | -20.21% |
| 2006 FY | 42.1 Million USD | -1.27% |
| 2006 Q4 | 7.94 Million USD | 0.23% |
| 2006 Q1 | 16.29 Million USD | 27.3% |
| 2006 Q2 | 9.93 Million USD | -39.03% |
| 2005 FY | 42.64 Million USD | 9.02% |
| 2005 Q2 | 9.95 Million USD | 6.06% |
| 2005 Q1 | 9.39 Million USD | -21.72% |
| 2005 Q3 | 10.49 Million USD | 5.36% |
| 2005 Q4 | 12.8 Million USD | 21.99% |
| 2004 Q2 | 9.54 Million USD | 6.2% |
| 2004 Q4 | 11.99 Million USD | 39.79% |
| 2004 Q3 | 8.58 Million USD | -10.13% |
| 2004 FY | 39.11 Million USD | 53.56% |
| 2004 Q1 | 8.99 Million USD | 1.67% |
| 2003 FY | 25.47 Million USD | 28.61% |
| 2003 Q3 | 6.47 Million USD | 25.7% |
| 2003 Q2 | 5.14 Million USD | 2.73% |
| 2003 Q1 | 5.01 Million USD | -12.1% |
| 2003 Q4 | 8.84 Million USD | 36.66% |
| 2002 Q2 | 5.25 Million USD | 40.73% |
| 2002 Q1 | 3.73 Million USD | -18.23% |
| 2002 Q3 | 5.1 Million USD | -2.87% |
| 2002 Q4 | 5.7 Million USD | 11.61% |
| 2002 FY | 19.8 Million USD | 51.48% |
| 2001 Q1 | 2.86 Million USD | -59.55% |
| 2001 Q4 | 4.57 Million USD | 72.19% |
| 2001 FY | 13.07 Million USD | 2.44% |
| 2001 Q3 | 2.65 Million USD | -12.5% |
| 2001 Q2 | 3.03 Million USD | 5.9% |
| 2000 Q4 | 7.08 Million USD | 216.12% |
| 2000 Q3 | 2.24 Million USD | 17.4% |
| 2000 Q2 | 1.9 Million USD | 24.46% |
| 2000 Q1 | 1.53 Million USD | 20.05% |
| 2000 FY | 12.76 Million USD | 137.34% |
| 1999 Q1 | 2 Million USD | 5.26% |
| 1999 Q4 | 1.27 Million USD | 41.89% |
| 1999 Q3 | 900 Thousand USD | -25.0% |
| 1999 FY | 5.37 Million USD | -32.79% |
| 1999 Q2 | 1.2 Million USD | -40.0% |
| 1998 Q4 | 1.9 Million USD | 46.15% |
| 1998 Q3 | 1.3 Million USD | -45.83% |
| 1998 Q2 | 2.4 Million USD | 4.35% |
| 1998 Q1 | 2.3 Million USD | -72.29% |
| 1998 FY | 8 Million USD | -19.19% |
| 1997 Q2 | 500 Thousand USD | 66.67% |
| 1997 Q1 | 300 Thousand USD | 175.0% |
| 1997 Q3 | 400 Thousand USD | -20.0% |
| 1997 FY | 9.9 Million USD | 607.14% |
| 1997 Q4 | 8.3 Million USD | 1975.0% |
| 1996 Q4 | -400 Thousand USD | -150.0% |
| 1996 Q3 | 800 Thousand USD | 100.0% |
| 1996 Q2 | 400 Thousand USD | -20.0% |
| 1996 FY | 1.4 Million USD | -51.72% |
| 1996 Q1 | 500 Thousand USD | 120.0% |
| 1995 Q4 | -2.5 Million USD | 0.0% |
| 1995 Q2 | 500 Thousand USD | 400.0% |
| 1995 FY | 2.9 Million USD | 0.0% |
| 1995 Q3 | - USD | -100.0% |
| 1995 Q1 | 100 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1207.218% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -246.229% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 40.93% |
| Nascent Biotech, Inc. | 2.22 Million USD | -682.868% |
| Rebus Holdings, Inc. | 664 Thousand USD | -2529.066% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 53.143% |
| Qrons Inc. | 643.67 Thousand USD | -2612.075% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -4381.141% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 69.608% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -4101.656% |
| Skye Bioscience, Inc. | 13.54 Million USD | -28.857% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 79.885% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -254.968% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -6569.953% |
| SQZ Biotechnologies Company | 85.61 Million USD | 79.611% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -498.614% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1062.328% |
| Mesoblast Limited | 5.9 Million USD | -195.781% |
| Marizyme, Inc. | 19.23 Million USD | 9.266% |
| Genus plc | 147.7 Million USD | 88.181% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -98.844% |
| Pharming Group N.V. | 225.49 Million USD | 92.258% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -752.099% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1201.261% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -109.342% |
| ContraFect Corporation | 56.88 Million USD | 69.314% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -295.97% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1080.522% |
| IMV Inc. | 37.7 Million USD | 53.706% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -525.619% |
| MultiCell Technologies, Inc. | 567.42 USD | -3076457.048% |
| ONE Bio Corp. | 6.44 Million USD | -170.908% |
| Accustem Sciences Inc. | 3.74 Million USD | -365.965% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 79.688% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -3181.625% |
| Q BioMed Inc. | 3.43 Million USD | -407.969% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 29.367% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -564.39% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1655.916% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 82.425% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -892.057% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -159.854% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -836.348% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 69928.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -9.036% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -851.286% |
| GB Sciences, Inc. | 1.42 Million USD | -1128.926% |
| Alpha Cognition Inc. | 9.7 Million USD | -79.865% |
| HST Global, Inc. | 140.9 Thousand USD | -12289.023% |
| CSL Limited | 3.44 Billion USD | 99.494% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1451.857% |
| Halberd Corporation | 74.84 Thousand USD | -23225.138% |
| Enzolytics Inc. | 2.17 Million USD | -700.961% |
| Agentix Corp. | 1.37 Million USD | -1172.602% |
| Resverlogix Corp. | 12.71 Million USD | -37.327% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -378.181% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.862% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1572.126% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -625.883% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1005.325% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -412.69% |
| AVAX Technologies, Inc. | 7.31 Million USD | -138.801% |
| Zenith Capital Corp. | 8.94 Million USD | -95.203% |
| Genscript Biotech Corporation | 825.34 Million USD | 97.885% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -100106.647% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -610.988% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -10078.475% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -808.79% |
| Kadimastem Ltd | 2.41 Million USD | -624.323% |
| Helix BioMedix, Inc. | 1.97 Million USD | -785.228% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -60.642% |
| BioStem Technologies, Inc. | 22.97 Million USD | 24.017% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -9518.977% |
| LadRx Corporation | 3.81 Million USD | -357.974% |
| Cell Source, Inc. | 4.32 Million USD | -303.598% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1790.288% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1790.288% |
| NovAccess Global Inc. | 2.46 Million USD | -607.689% |
| Affymax, Inc. | 39.38 Million USD | 55.677% |
| Itoco Inc. | 919.14 Thousand USD | -1799.269% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -311.876% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1460.054% |
| Mobile Lads Corp. | 554.54 Thousand USD | -3047.981% |
| CytoDyn Inc. | 18.05 Million USD | 3.328% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -69259.132% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -7832.188% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1129.546% |
| SYBLEU INC | 160.87 Thousand USD | -10751.215% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -861.119% |
| International Stem Cell Corporation | 5.27 Million USD | -231.19% |
| Bioxytran, Inc. | 3.82 Million USD | -356.972% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -33061.734% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -85713.302% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 51.864% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -978.925% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -2272.407% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -461.138% |
| Neutra Corp. | 243.82 Thousand USD | -7059.761% |
| PureTech Health plc | 144.59 Million USD | 87.927% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 14.802% |
| IXICO plc | 4.7 Million USD | -270.873% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -98.443% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 85.174% |
| CSL Limited | 3.89 Billion USD | 99.552% |
| Cellectis S.A. | 97.32 Million USD | 82.062% |